Mast Cell Disease Research
Our charity works to connect patients to clinical trials and research studies on mast cell diseases for which they may be eligible and raises money to support research into mast cell diseases.
Patients with advanced forms of mastocytosis (Aggressive Systemic Mastocytosis, Systemic Mastocytosis with Associated Haematologic Neoplasm and Mast Cell Leukaemia) may be eligible for ongoing trials of a medication from Blueprint Medicines called Avapritinib (BLU-285). For more information about the drug and the study, you may visit Blueprint Medicine
Blueprint Medicines have also announced their intention to run a trial of Avapritinib in people with indolent and smouldering systemic mastocytosis. The details of when those trials will begin have not yet been announced.
Blueprint recently held an webinar on their new trials which can be viewed until October 17, 2018.
Please contact us if you would like to learn more about these trials in the UK.
Deciphera Pharmaceuticals is running a Phase 1 trial to establish the proper dose and tolerability of DCC-2618 in patients with advanced forms of mastocytosis. For more information about the drug, you may visit Deciphera Pharmaceuticals. Please contact us if you would like to learn more about these trials in the UK.
A research group in the UK has recently launched a small study looking at Hereditary Alpha Tryptasaemia. For more information please contact us.
When funds allow, we make grants to researchers for research on mast cells and mast cell diseases. Email us to learn more.